GBI Research

GBI Research provides industry-leading global business intelligence solutions. Our products and services help companies make better business decisions, win business and position themselves more effectively. GBI Research publishes more than 100 research reports per annum across a wide range of industries. Our reports draw on in-depth primary and secondary research, databases of proprietary in-house data and high quality analysis from our expert teams. GBI Research employs hundreds of highly qualified Analysts across the US, Europe and Asia. Key report types currently published by GBI Research i
nclude:

  • Market Intelligence Reports: premium analytical reports based on a combination of market data, company, deals and project content, industry surveys and additional primary and secondary research.
  • Benchmarking Reports: analytical reports comparing key financial indicators for the top 20 companies in a particular industry and geography.
  • Industry Outlook Reports: survey-based reports, revealing and analyzing the leading experts' opinions on the future of the industry covered.
  • Market Profiles: overview-level reports based on market, company and demographic data.
  • Pipeline Analysis Reports: reports analyzing the unmet need, market size and product pipeline for different disease indications, based on a detailed database of developmental products.
GBI Research
 

List of reports from GBI Research

2  3  4  5    7    9  10  11  
Emerging Pharmaceutical Market in Indonesia and Philippines - 100% Foreign Direct Investment in Indonesia and Extensive Insurance Coverage in the Philippines Attract Foreign Pharma Companies
6/4/2012 | published by: GBI Research
... and Philippines - 100% Foreign Direct Investment in Indonesia and Extensive Insurance Coverage in the Philippines Attract Foreign Pharma Companies”, provides an in-depth analysis of trends, issues and challenges in the pharmaceutical market in Indonesia ...  |  read more...
$3,500.00
Drug Price Cuts in Top Five Countries of Europe - Tougher Reference Pricing Environment and Drug Price Freeze through 2013 Expected to Drive Down Healthcare Costs
5/18/2012 | published by: GBI Research
... released its latest research “Drug Price Cuts in Top Five Countries of Europe - Tougher Reference Pricing Environment and Drug Price Freeze through 2013 Expected to Drive Down Healthcare Costs”. It provides a comprehensive overview ...  |  read more...
$3,500.00
Antibacterials Market to 2017 - Innovative Anti-Infectives that Target MDR Gram-Negative Pathogens Offer Significant Revenue Potential
5/18/2012 | published by: GBI Research
... Anti-Infectives that Target MDR Gram-Negative Pathogens Offer Significant Revenue Potential”, which provides key data, information and analysis for the global antibacterials market (covering tuberculosis, pneumonia, urinary tract infections, atypical bronchitis, tonsillitis, sinusitis and otitis media ...  |  read more...
$3,500.00
Arthritis Therapeutics Market to 2018 - Novel Oral JAK Inhibitors and Biologic Disease Modifying Anti-Rheumatic Drugs (DMARD) Will Drive Continued Growth Across Key Indications
5/18/2012 | published by: GBI Research
... Novel Oral JAK Inhibitors and Biologic Disease Modifying Anti-Rheumatic Drugs (DMARD) Will Drive Continued Growth Across Key Indications”, provides an expert insight into the global arthritis market and market forecast until 2018. The report is ...  |  read more...
$3,500.00
Patient Perspectives - Patient Reported Outcomes Drive Drug Development, but Improving Patient Involvement Remains a Challenge
5/18/2012 | published by: GBI Research
... Drive Drug Development, but Improving Patient Involvement Remains a Challenge”. The report examines the role of patients in changing the research agenda and helping pharma companies to bring effective medicines that meet real unmet medical ...  |  read more...
$3,500.00
Pricing and Reimbursement in Brazil - Health Technology Assessment (HTA) Studies to Facilitate Setting of Ceiling Prices for New Drugs
5/18/2012 | published by: GBI Research
... Reimbursement in Brazil - Health Technology Assessment (HTA) Studies to Facilitate Setting of Ceiling Prices for New Drugs”. It provides a comprehensive overview of the healthcare system, and pricing and reimbursement process in Brazil with ...  |  read more...
$3,500.00
Prescribing Trends in Opioids - Driven by Efficacy Advantages, Opioids to Remain the Mainstay of Breakthrough Pain Management
5/18/2012 | published by: GBI Research
... - Driven by Efficacy Advantages, Opioids to Remain the Mainstay of Breakthrough Pain Management”, provides in-depth analysis of unmet needs, drivers and barriers that impact the opioids market. The report analyzes current method of practice ...  |  read more...
$3,500.00
Generics in Cardiovascular Diseases Market to 2018 - Loss of Lipitor Market Exclusivities and Impending Patent Expirations of Plavix to Drive Generic Substitution
5/18/2012 | published by: GBI Research
... research “Generics in Cardiovascular Diseases Market to 2018 - Loss of Lipitor Market Exclusivities and Impending Patent Expirations of Plavix to Drive Generic Substitution”. The report provides in-depth analysis of drivers and barriers that impact ...  |  read more...
$3,500.00
Orphan Disease Therapeutics in Genetic Disorders to 2018 - Emerging Agents in Cystic Fibrosis Offer Strong Opportunities for Investment and Licensing Activity
5/15/2012 | published by: GBI Research
... research, “Orphan Disease Therapeutics in Genetic Disorders to 2018 - Emerging Agents in Cystic Fibrosis Offer Strong Opportunities for Investment and Licensing Activity”, which provides insights into the global orphan diseases in genetic disorders therapeutics ...  |  read more...
$3,500.00
Autoimmune Disorders Therapeutics Market to 2017 - Launch of Gilenya and Benlysta to Drive the Growth of Multiple Sclerosis and Systemic Lupus Erythematosus Therapeutic Segments
4/30/2012 | published by: GBI Research
... its latest research “Autoimmune Disorders Therapeutics Market to 2017 - Launch of Gilenya and Benlysta to Drive the Growth of Multiple Sclerosis and Systemic Lupus Erythematosus Therapeutic Segments”, which provides insights into autoimmune disease therapeutics ...  |  read more...
$3,500.00
Regulatory Intelligence on Medical Device Recalls - Ineffective Process Control, Defects in Design of Device, Software or Other Components are the Major Reasons for Recall
4/30/2012 | published by: GBI Research
... - Ineffective Process Control, Defects in Design of Device, Software or Other Components are the Major Reasons for Recall”, provides an in-depth analysis on medical device recalls in the US. The report analyzes the number ...  |  read more...
$3,500.00
Oral Drug Delivery Market to 2017 - Out-licensing Proprietary Technologies for Proteins, Peptides and Small Molecules to Drive Revenue Growth
4/30/2012 | published by: GBI Research
... Delivery Market to 2017 - Out-licensing Proprietary Technologies for Proteins, Peptides and Small Molecules to Drive Revenue Growth”. The report focuses on the current scenario of orally administered drugs. Key segment of orally administered drugs ...  |  read more...
$3,500.00
Orphan Diseases Therapeutics in Oncology to 2018 - Strongly Diversified Developmental Pipelines Indicate Long-Term Growth Potential despite Moderate Scope of Current Late Stage Molecules
4/30/2012 | published by: GBI Research
... latest research “Orphan Diseases Therapeutics in Oncology to 2018 - Strongly Diversified Developmental Pipelines Indicate Long-Term Growth Potential despite Moderate Scope of Current Late Stage Molecules”, which provides insights into the Oncology orphan disease therapeutics ...  |  read more...
$3,500.00
Cytotoxic Therapies Market to 2017 - Launch of Next Generation Camptothecin Analogues Will Help Offset Revenue Loss due to Generic Erosion
4/30/2012 | published by: GBI Research
... Therapies Market to 2017 - Launch of Next Generation Camptothecin Analogues Will Help Offset Revenue Loss due to Generic Erosion”, which provides insights into the cytotoxic therapies market until 2017 for eight oncology indications. The ...  |  read more...
$3,500.00
Orphan Disease Therapeutics Market to 2018 - Improved Understanding of Rare Diseases' Heterogeneity and Novel New Clinical Trial Designs to Foster Innovation
4/30/2012 | published by: GBI Research
... “Orphan Disease Therapeutics Market to 2018 - Improved Understanding of Rare Diseases' Heterogeneity and Novel New Clinical Trial Designs to Foster Innovation”, which provides insights into the orphan disease therapeutics market until 2018. The report ...  |  read more...
$3,500.00
Antivirals Market to 2017 - Increased Uptake of High Priced Combination Drugs will Offset the Impact of Generics in the HIV Therapeutics Market
4/20/2012 | published by: GBI Research
... research “Antivirals Market to 2017 - Increased Uptake of High Priced Combination Drugs will Offset the Impact of Generics in the HIV Therapeutics Market”, which essentially provides insights into antivirals therapeutics sales forecasts until 2017. ...  |  read more...
$3,500.00
Pricing and Reimbursement in Generics - European Austerity Measures and Healthcare Cost Containment Puts Innovation-Driven Pharma Companies under Pressure
4/20/2012 | published by: GBI Research
... in Generics - European Austerity Measures and Healthcare Cost Containment Puts Innovation-Driven Pharma Companies under Pressure”. The report provides a comprehensive overview of the healthcare expenditure, healthcare regulatory system, and pricing and reimbursement process with ...  |  read more...
$3,500.00
Contract Research Organizations (CROs) Market to 2018 - Public-Private Partnerships to Strengthen Research Capacities and Advance Clinical Development Programs
4/20/2012 | published by: GBI Research
... (CROs) Market to 2018 - Public-Private Partnerships to Strengthen Research Capacities and Advance Clinical Development Programs”, which provides key data, information and analysis of CRO industry. The report provides a comprehensive insight into the size ...  |  read more...
$3,500.00
Rx-to-OTC Switching Strategies - New Switching Opportunities in Weight Management and Smoking Cessation, but Encouraging the Uptake of Self-Medication Remains a Challenge
4/20/2012 | published by: GBI Research
... “Rx-to-OTC Switching Strategies - New Switching Opportunities in Weight Management and Smoking Cessation, but Encouraging the Uptake of Self-Medication Remains a Challenge” examines the key issues influencing the global OTC market and assesses why companies ...  |  read more...
$3,500.00
Contract Manufacturing Organizations to 2018 - Cost Advantages and Improving Quality Standards Build Confidence and Encourage Foreign Investment in Asian CMOs
4/20/2012 | published by: GBI Research
... Manufacturing Organizations to 2018 - Cost Advantages and Improving Quality Standards Build Confidence and Encourage Foreign Investment in Asian CMOs”, which provides key data, information and analysis of the Contract Manufacturing Organization (CMO) industry. The ...  |  read more...
$3,500.00
Growth Strategies for Supergenerics Organizations - Opportunities in Addressing Unmet Medical Needs and Providing Cost-Effective Solutions for Product Development in Emerging Markets
4/20/2012 | published by: GBI Research
... “Growth Strategies for Supergenerics Organizations - Opportunities in Addressing Unmet Medical Needs and Providing Cost-Effective Solutions for Product Development in Emerging Markets” which assesses the strategies that companies have used to improve the efficacy, safety, ...  |  read more...
$3,500.00
Renal Dialysis Equipment Market to 2017- Lower Costs and Similar Efficacy Rates as Hemodialysis to Increase Adoption Rates of Peritoneal Dialysis
4/2/2012 | published by: GBI Research
... Efficacy Rates as Hemodialysis to Increase Adoption Rates of Peritoneal Dialysis” shows rapid growth in the number of End Stage Renal Disease (ESRD) patients owing to the growing prevalence of diabetes, hypertension and an increasingly ...  |  read more...
$3,500.00
Pricing and Reimbursement in Russia - Big Pharma Take Advantage of Reimbursement for Costly Drugs Through the DLO’s Seven Nosologies Program
4/2/2012 | published by: GBI Research
... and Reimbursement in Russia - Big Pharma Take Advantage of Reimbursement for Costly Drugs Through the DLO’s Seven Nosologies Program”. It provides a comprehensive overview of the healthcare system, and pricing and reimbursement process in ...  |  read more...
$3,500.00
Orphan Diseases Therapeutics in CNS to 2017 - Novel Agents such as AMR101 and ACR16 to Provide Treatment Options and Boost the Huntington’s Disease Segment
4/2/2012 | published by: GBI Research
... its latest research “Orphan Diseases Therapeutics in CNS to 2017 - Novel Agents such as AMR101 and ACR16 to Provide Treatment Options and Boost the Huntington’s Disease Segment”, which provides insights into the CNS orphan ...  |  read more...
$3,500.00
Herpes Market to 2018 - Genericization Compels Competitors Seeking Differentiation to Adopt Novel Drug Delivery Technologies
4/1/2012 | published by: GBI Research
... Technologies finds that the global herpes market is an attractive one, and is expected to witness growth during the forecast period and to provide good opportunities for investors. The expected high growth is attributed to ...  |  read more...
$3,500.00
2  3  4  5    7    9  10  11  
 
US: 800.298.5699
Int'l: +1.240.747.3093
 
Join Alert Me now!
Receive bi-weekly email alerts on new market research

Sign up today!